Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.

Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog

Background. Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the effects of quarterly infusion of zoledronic acid on bone mineral density (BMD) and markers of bone turnover over a one-year period in men receiving gonadotropin-releasing hormone analog (GnRH-a) for prostate cancer. Methods. 41 subjects were randomly assigned to treatment w...

Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.

BACKGROUND Secondary hyperparathyroidism is frequent in prostate cancer patients with bone metastases, and this condition is worsened by the administration of potent bisphosphonates. Serum parathyroid hormone (PTH) elevation can impair the efficacy of these drugs in terms of survival. METHODS The prognostic role of elevated serum PTH levels at baseline and after 3 months of zoledronic acid ad...

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

BACKGROUND Bone metastases are a common cause of morbidity in patients with prostate carcinoma. We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with bone metastases. METHODS Patients with hormone-refractory prostate cancer and a history of bone metastases were randomly assigned to a double-bli...

Re: A Randomized, Placebo- Controlled Trial of Zoledronic Acid in Patients with Hormone- Refractory Metastatic Prostate Carcinoma

The article by Saad et al. (1) indicated clinical benefit for the use of zoledronic acid in the treatment of bone metastases and androgen-independent prostate cancer. However, the precise nature and biologic implication of the clinical benefit deserves further scrutiny. The endpoint used to determine clinical benefit was “skeletal-related events.” However, only “pathologic bone fracture” was st...

Investigating the Role of Zoledronic Acid on Interleukin-6 Cytokine Expression in Prostate Cancer Cell Lines